Abstract 406P
Background
Due to the increasing number of trials with immune checkpoint inhibitors (ICI) in first line therapy of non–small cell lung cancer (NSCLC), we performed a systematic review and meta-analyses about the differences between anti PD-1 and PD-L1 in naïve-treatment NSCLC patients through adjusted indirect analysis to minimize the potential bias regarding overall survival (OS), progression free survival (PFS), overall response rate (ORR) and grade 3-5 adverse event (AE).
Methods
We included studies published until May 30 2020. Applicable terms, such as “lung cancer AND first line AND immunotherapy OR PD-1 OR PL-D1,” were used. Primary outcomes were OS, PFS, ORR and grade 3-5 AE. We used the random-effects model to generate pooled estimates for proportions. Meta-analyses using pooled risk ratios were performed for binary outcomes from comparative studies with the random effect model. As there are no studies with direct analyzes between PD-1 and PD-L1 treatments, we carry out indirect data analyzes using the Excel spreadsheet. All analyses were performed by REVMAN version 5.0.
Results
Thirteen studies met our eligibility criteria, including 7673 patients (4077 cases in experimental and 3596 cases in control group). Six trials investigated ICI in monotherapy (four of them with anti-PD-1 and three with anti-PD-L1) and seven trials investigated ICI-chemotherapy combination; three used Pembrolizumabe and four used Atezolizumabe. Related to prognosis, in the ICI-chemotherapy combination group, anti-PD-1 were associated with better OS (P=0.02) and PFS (P=0.03) compared to anti-PD-L1. In monotherapy, there was no statistical difference between the use of anti-PD-1 and anti-PD-L1 for OS and PFS. Regarding ORR and toxicity, in the ICI-chemotherapy combination group, anti-PD-1 was associated with a trand better ORR (p=0.12) and less frequent grade 3-5 AE compared to the use of anti-PD-L1. In monotherapy, no statistical difference between the use of anti-PD-1 and anti-PD-L1 was observed.
Conclusions
Our study suggests that the combination of anti-PD-1 and chemotherapy is superior to anti-PD-L1 + chemotherapy in 1st line NSCLC therapy; in monotherapy both strategies appear to be similar.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
371P - Real-world insights into treatment patterns and outcomes in stage III non-small cell lung cancer (NSCLC): KINDLE study India analysis
Presenter: Kumar Prabhash
Session: e-Poster Display Session
372P - Treatment patterns and outcomes in stage III non-small cell lung cancer (NSCLC): Real-world experience in Singapore from the KINDLE study
Presenter: Ross A. Soo
Session: e-Poster Display Session
373P - Chromatin accessibility reveals potential prognostic value of the peak set associated with smoking history in patients with lung adenocarcinoma
Presenter: Jianlian Deng
Session: e-Poster Display Session
384P - BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC
Presenter: Stefanie Schalm
Session: e-Poster Display Session
385P - Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTRK-2 study
Presenter: Fabrice Barlesi
Session: e-Poster Display Session
386P - A single-arm phase Ib study of autologous cytokine-induced killer (CIK) cell immunotherapy in combination with sintilimab plus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)
Presenter: LI Zhou
Session: e-Poster Display Session
387P - Phase Ib study of savolitinib ± osimertinib in Japanese patients (pts) with advanced solid malignancies & EGFRm NSCLC: TATTON part C
Presenter: Tomonori Hirashima
Session: e-Poster Display Session
388P - Biosimilar TAB008 compared with bevacizumab in advanced non-squamous, non-small cell, EGFR wildtype lung cancer patients
Presenter: Zhen Zhou
Session: e-Poster Display Session
389P - Updated analysis from the KEYNOTE-042 China study: 1L pembrolizumab (pembro) vs chemotherapy (chemo) in Chinese patients (pts) with advanced NSCLC with PD-L1 TPS ≥1%
Presenter: Yi-Long Wu
Session: e-Poster Display Session
391P - Economic impact of next-generation sequencing (NGS) versus single-gene testing modalities to detect genomic alterations (GAs) in metastatic non-small cell lung cancer (mNSCLC) in Asia
Presenter: Herbert Loong
Session: e-Poster Display Session